Opexa Therapeutics:

Precision Immunotherapy™


Personalized T-cell immunotherapy


A phase II clinical study for patients with Secondary Progressive Multiple Sclerosis

NASDAQ: OPXA: $ 1.09
CHANGE: -0.06CHANGE: -5.22% Volume: 337,676 September 19, 2014

Corporate Overview

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific immunotherapies for the treatment of multiple sclerosis. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis.

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders.


Tcelna® (imilecleucel-T) is an autologous T-cell immunotherapy being developed for the treatment of Multiple Sclerosis (MS), and is specifically tailored to each patient's immune response profile to myelin.
The Abili-T trial is Opexa's ongoing randomized, double-blind, placebo-controlled phase IIb clinical study of Tcelna in Secondary Progressive Multiple Sclerosis (SPMS) subjects.